REVIEW OF BASIC CLINICAL TRIALS OF ALENDRONATE
https://doi.org/10.14412/1996-7012-2010-591
Abstract
Development
Bisphosphonates are a major class of drugs used to treat osteoporosis (OP) and other diseases characterized by increased bone resorption. The
literature contains indisputable evidence for the efficacy of alendronate in the registered oral dose of 70 mg once weekly in the treatment of postmenopausal
OP. Alendronate reduces a risk for vertebral and non-vertebral (peripheral) fractures, including those of the hip and forearm. Just
one-year therapy with the drug results in increased bone mineral density and decreased bone resorption, which is associated with a reduced risk
for osteoporotic fractures. Undesirable side effects of alendronate are rare, if it is correctly used, and generally appear as dyspeptic events in the
upper gastrointestinal tract. In addition to its antiresorptive effect on the bone, the combination drug (alendronate 70 mg/cholecalciferol 2800
IU) additionally elevates the serum level of vitamin D, which allows the patients to be simultaneously treated with the drugs of the two groups
(a bisphosphonate and vitamin D) recommended for use by the Russian Osteoporosis Association.
Bisphosphonates are a major class of drugs used to treat osteoporosis (OP) and other diseases characterized by increased bone resorption. The
literature contains indisputable evidence for the efficacy of alendronate in the registered oral dose of 70 mg once weekly in the treatment of postmenopausal
OP. Alendronate reduces a risk for vertebral and non-vertebral (peripheral) fractures, including those of the hip and forearm. Just
one-year therapy with the drug results in increased bone mineral density and decreased bone resorption, which is associated with a reduced risk
for osteoporotic fractures. Undesirable side effects of alendronate are rare, if it is correctly used, and generally appear as dyspeptic events in the
upper gastrointestinal tract. In addition to its antiresorptive effect on the bone, the combination drug (alendronate 70 mg/cholecalciferol 2800
IU) additionally elevates the serum level of vitamin D, which allows the patients to be simultaneously treated with the drugs of the two groups
(a bisphosphonate and vitamin D) recommended for use by the Russian Osteoporosis Association.
References
1. <div><p>Российская ассоциация по остеопорозу. Клинические рекомендации. Остеопороз. Диагностика, профилактика и лечение. Под ред.Л.И.Беневоленской. 2008.</p><p>Black D.M., Thompson D.E., Bauer D.C. and FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85(11):4118-24.</p><p>Cummings S.R., Black D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA1998;280:2077-82.</p><p>Liberman U.A., Weiss S.R., Broll J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333:1437-43.</p><p>Pols H.A., Felsenberg D., Hanley D.A. et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Osteoporos Int 1999;9:461-8.</p><p>Black D.M., Schwartz A.V., Ensrud K.E. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38.</p><p>Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.</p><p>Rodan G., Reszka A., Golub E. et al. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20:1291-300.</p><p>Rizzoli R., for The Alendronate OnceWeekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-96.</p><p>Schnitzer T., Bone H.G., Crepaldi G. et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 2000;12:1-12.</p><p>Rosen C.J., Hochberg M.C., Bonnick S.L. et al. for the Fosamax Actonel Comparison Trial Investigators. Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study. J Bone and Mineral Res 2005:20:141-51.</p><p>Recker R., Lips P., Felsenberg D. et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15 week randomized controlled trial. Curr Med Res and Op 2006;22:1745-55.</p><p>Wells G.A., Cranney A., Peterson J. et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (Review). Cochrane Database of Systematic Reviews 2008; Issue 1.</p></div><br />
Review
For citations:
Zotkin EG, Zotkin EG. REVIEW OF BASIC CLINICAL TRIALS OF ALENDRONATE. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2010;4(1):70-75. (In Russ.) https://doi.org/10.14412/1996-7012-2010-591
Views:
1424
Email this article 